keyword
MENU ▼
Read by QxMD icon Read
search

Colorectal liver secondaries

keyword
https://www.readbyqxmd.com/read/28717911/laparoscopic-compared-to-open-repeat-hepatectomy-for-colorectal-liver-metastases-a-multi-institutional-propensity-matched-analysis-of-short-and-long-term-outcomes
#1
Julie Hallet, Antonio Sa Cunha, Daniel Cherqui, Brice Gayet, Diane Goéré, Philippe Bachellier, Alexis Laurent, David Fuks, Francis Navarro, Patrick Pessaux
INTRODUCTION: While uptake of laparoscopic hepatectomy has improved, evidence on laparoscopic re-hepatectomy (LRH) for colorectal liver metastases (CRLMs) is limited and has never been compared to the open approach. We sought to define outcomes of LRH compared to open re-hepatectomy (ORH). METHODS: Patients undergoing re-hepatectomy for CRLM at 39 institutions (2006-2013) were identified. Primary outcomes were 30-day post-operative overall morbidity, mortality, and length of stay...
July 17, 2017: World Journal of Surgery
https://www.readbyqxmd.com/read/28657937/laparoscopic-versus-open-resection-for-colorectal-liver-metastases-the-oslo-comet-randomized-controlled-trial
#2
Åsmund Avdem Fretland, Vegar Johansen Dagenborg, Gudrun Maria Waaler Bjørnelv, Airazat M Kazaryan, Ronny Kristiansen, Morten Wang Fagerland, John Hausken, Tor Inge Tønnessen, Andreas Abildgaard, Leonid Barkhatov, Sheraz Yaqub, Bård I Røsok, Bjørn Atle Bjørnbeth, Marit Helen Andersen, Kjersti Flatmark, Eline Aas, Bjørn Edwin
OBJECTIVE: To perform the first randomized controlled trial to compare laparoscopic and open liver resection. SUMMARY BACKGROUND DATA: Laparoscopic liver resection is increasingly used for the surgical treatment of liver tumors. However, high-level evidence to conclude that laparoscopic liver resection is superior to open liver resection is lacking. METHODS: Explanatory, assessor-blinded, single center, randomized superiority trial recruiting patients from Oslo University Hospital, Oslo, Norway from February 2012 to January 2016...
June 27, 2017: Annals of Surgery
https://www.readbyqxmd.com/read/28634727/safety-and-efficacy-of-chemosaturation-in-patients-with-primary-and-secondary-liver-tumors
#3
Martha M Kirstein, Steffen Marquardt, Nils Jedicke, Silke Marhenke, Wolfgang Koppert, Michael P Manns, Frank Wacker, Arndt Vogel
BACKGROUND: Chemosaturation with percutaneous hepatic perfusion (CS-PHP; hepatic CHEMOSAT(®) delivery system; Delcath Systems Inc, USA) is a novel medical device, which delivers high doses of melphalan directly to the liver in patients with primary and secondary liver tumors while limiting systemic toxicity through hemofiltration of the hepatic venous blood. The aim of this study was to analyze the safety and efficacy of the second-generation CS-PHP after 54 treatments at Hannover Medical School, Germany...
June 20, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28633089/first-line-panitumumab-plus-folfox4-or-folfiri-in-colorectal-cancer-with-multiple-or-unresectable-liver-metastases-a-randomised-phase-ii-trial-planet-ttd
#4
Alfredo Carrato, Albert Abad, Bartomeu Massuti, Cristina Grávalos, Pilar Escudero, Federico Longo-Muñoz, José-Luis Manzano, Auxiliadora Gómez, María José Safont, Javier Gallego, Beatriz García-Paredes, Carles Pericay, Rosario Dueñas, Fernando Rivera, Ferrán Losa, Manuel Valladares-Ayerbes, Encarnación González, Enrique Aranda
BACKGROUND: In first-line wild-type (WT)-Kirsten rat sarcoma viral oncogene homologue (KRAS) metastatic colorectal cancer (mCRC), panitumumab (Pmab) improves outcomes when added to FOLFOX [folinic acid, 5-fluorouracil, and oxaliplatin] or FOLFIRI [folinic acid, 5-fluorouracil, and irinotecan]. However no trial has directly compared these combinations. METHODS: Multicentre, open-label study in untreated patients ≥ 18 years with (WT)-KRAS mCRC and multiple or unresectable liver-limited disease (LLD) randomised to either Pmab-FOLFOX4 or Pmab-FOLFIRI...
August 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28624558/safety-and-feasibility-of-electrochemotherapy-in-patients-with-unresectable-colorectal-liver-metastases-a-pilot-study
#5
Laura Coletti, Valentina Battaglia, Paolo De Simone, Laura Turturici, Carlo Bartolozzi, Franco Filipponi
BACKGROUND AND OBJECTIVES: Electrochemotherapy is a novel ablation technique combining chemotherapeutic agents with reversible cell membrane electroporation. Previous experiences have shown its efficacy for cutaneous tumors. Its application for deep-seated malignancies is under investigation. We performed a prospective, pilot study to evaluate the feasibility, safety, and efficacy of intraoperative electrochemotherapy for otherwise unresectable colorectal liver metastases. METHODS: Electrochemotherapy with bleomycin was combined with open liver resection and performed with linear or hexagonal needle electrodes according to an individualized pretreatment plan...
June 15, 2017: International Journal of Surgery
https://www.readbyqxmd.com/read/28620089/development-and-validation-of-risk-prediction-equations-to-estimate-survival-in-patients-with-colorectal-cancer-cohort-study
#6
Julia Hippisley-Cox, Carol Coupland
Objective To develop and externally validate risk prediction equations to estimate absolute and conditional survival in patients with colorectal cancer. Design Cohort study.Setting General practices in England providing data for the QResearch database linked to the national cancer registry.Participants 44 145 patients aged 15-99 with colorectal cancer from 947 practices to derive the equations. The equations were validated in 15 214 patients with colorectal cancer from 305 different QResearch practices and 437 821 patients with colorectal cancer from the national cancer registry...
June 15, 2017: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/28615696/intraoperative-imaging-of-hepatic-cancers-using-%C3%AE-glutamyltranspeptidase-specific-fluorophore-enabling-real-time-identification-and-estimation-of-recurrence
#7
Yoichi Miyata, Takeaki Ishizawa, Mako Kamiya, Suguru Yamashita, Kiyoshi Hasegawa, Aya Ushiku, Junji Shibahara, Masashi Fukayama, Yasuteru Urano, Norihiro Kokudo
γ-Glutamyltranspeptidase (GGT) is upregulated in a variety of human cancers including primary and secondary hepatic tumors. This motivated us to use γ-glutamyl hydroxymethyl rhodamine green (gGlu-HMRG), a novel fluorophore emitting light at around 520 nm following enzymatic reaction with GGT, as a tool for the intraoperative identification of hepatic tumors. gGlu-HMRG was topically applied to 103 freshly resected hepatic specimens. Fluorescence imaging using gGlu-HMRG identified hepatic tumors with the sensitivity/specificity of 48%/96% for hepatocellular carcinoma, 100%/100% for intrahepatic cholangiocarcinoma, and 87%/100% for colorectal liver metastasis...
June 14, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28588612/the-roles-of-carcinoembryonic-antigen-in-liver-metastasis-and-therapeutic-approaches
#8
REVIEW
Joo Han Lee, Seong-Wook Lee
Metastasis is a highly complicated and sequential process in which primary cancer spreads to secondary organic sites. Liver is a well-known metastatic organ from colorectal cancer. Carcinoembryonic antigen (CEA) is expressed in most gastrointestinal, breast, and lung cancer cells. Overexpression of CEA is closely associated with liver metastasis, which is the main cause of death from colorectal cancer. CEA is widely used as a diagnostic and prognostic tumor marker in cancer patients. It affects many steps of liver metastasis from colorectal cancer cells...
2017: Gastroenterology Research and Practice
https://www.readbyqxmd.com/read/28579681/making-the-case-intra-arterial-therapy-for-less-common-metastases
#9
REVIEW
Andrew C Gordon, Omar M Uddin, Ahsun Riaz, Riad Salem, Robert J Lewandowski
Intra-arterial therapies have high antitumor activity for both primary and secondary hepatic malignancies. Selective infusions allow increased delivery of cytoreductive therapy to the tumor bed while sparing the normal hepatic parenchyma. These therapies are now often applied in the outpatient setting or with short overnight hospital stays and have a growing role in the treatment of liver-dominant disease from metastatic colorectal cancer and from neuroendocrine tumors. Less commonly, intra-arterial therapies are applied to treat secondary hepatic malignancies from breast cancer, melanoma, pancreatic adenocarcinoma, and soft-tissue sarcomas...
June 2017: Seminars in Interventional Radiology
https://www.readbyqxmd.com/read/28501254/cytoreduction-and-hyperthermic-intraperitoneal-chemotherapy-in-the-management-of-colorectal-peritoneal-metastasis
#10
REVIEW
Bradley Hall, James Padussis, Jason M Foster
Historically, patients with peritoneal carcinomatosis secondary to colorectal cancer have a poor overall prognosis. Recent data support the use of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS + HIPEC) to specifically address the peritoneal disease. Retrospective studies on CRS + HIPEC have been promising, showing significant improvements in OS compared with systemic chemotherapy alone. However, CRS + HIPEC carries morbidity similar to other advance oncology procedures such as liver resection and pancreatoduonectomy...
June 2017: Surgical Clinics of North America
https://www.readbyqxmd.com/read/28495435/validation-of-clinical-risk-score-for-colorectal-liver-metastases-resected-in-a-contemporary-multicenter-cohort
#11
Paul Beamish, Madeline Lemke, Jennifer Li, Elijah Dixon, Mauro T Abraham, Roberto Hernandez Alejandro, Sean Bennett, Guillaume Martel, Paul J Karanicolas
BACKGROUND: Recent advances in care for colorectal liver metastases (CRLM) have lengthened 5-year survival. In this new era, prognostic tools such as the clinical risk score (CRS) for colorectal liver metastases require reevaluation. METHODS: Patients undergoing resection for CRLM between 2008 and 2012 at 4 specialty hepatobiliary centers in Canada (N = 740) were stratified by CRS and analyzed in Kaplan-Meier survival curves. Primary outcome of overall survival (OS) and secondary outcome of recurrence-free survival (RFS)...
May 8, 2017: HPB: the Official Journal of the International Hepato Pancreato Biliary Association
https://www.readbyqxmd.com/read/28445277/cancer-studies-based-on-secondary-data-analysis-of-the-taiwan-s-national-health-insurance-research-database-a-computational-text-analysis-and-visualization-study
#12
Jui-Kun Chiang, Chih-Wen Lin, Chun-Lung Wang, Malcolm Koo, Yee-Hsin Kao
There has been a surge in the academic publication output based on secondary analyses of the data from the Taiwan's National Health Insurance claim records. It has become a challenge to comprehend such a rapid expansion of the literature. Therefore, this study aimed to explore the conceptual content of National Health Insurance Research Database-based cancer research, using the abstract of articles extracted from PubMed between 2002 and 2015. Search terms including "National Health Insurance Research Database (NHIRD) AND Taiwan," "Taiwan AND population-based," and "Taiwan AND nationwide" were used to search in PubMed with the publication date limited to between 1997 and 2015...
April 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28433600/hepatic-arterial-infusion-chemotherapy-for-unresectable-liver-metastases-of-colorectal-cancer-a-multicenter-retrospective-study
#13
REVIEW
Annie Lim, Samuel Le Sourd, Hélène Senellart, Dominique Luet, Frédéric Douane, Christophe Perret, Antoine Bouvier, Sylvie Métairie, Estelle Cauchin, Philippe Rougier, Tamara Matysiak-Budnik, Yann Touchefeu
Hepatic arterial infusion chemotherapy (HAIC) is a treatment used for liver metastases (LM) of colorectal cancer (CRC). Because of its technical conditions, it has been used in only a few experienced centers in France. Our aim was to evaluate its feasibility, efficacy and tolerance in 4 centers. Clinical, biological, and radiological data of patients treated with HAIC for unresectable LM from CRC in 4 institutions from October 2011 to January 2016 were retrospectively analyzed. Sixty-one patients with unresectable LM from CRC were included...
March 14, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28417463/pharmacological-interventions-for-primary-sclerosing-cholangitis-an-attempted-network-meta-analysis
#14
REVIEW
Francesca Saffioti, Kurinchi Selvan Gurusamy, Neil Hawkins, Clare D Toon, Emmanuel Tsochatzis, Brian R Davidson, Douglas Thorburn
BACKGROUND: Primary sclerosing cholangitis is a chronic cholestatic liver disease that is associated with both hepatobiliary and colorectal malignancies, which can result in liver cirrhosis and its complications. The optimal pharmacological treatment for patients with primary sclerosing cholangitis remains controversial. OBJECTIVES: To assess the comparative benefits and harms of different pharmacological interventions in people with primary sclerosing cholangitis by performing a network meta-analysis, and to generate rankings of available pharmacological interventions according to their safety and efficacy...
March 28, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28352187/risk-of-subsequent-primary-malignancies-among-patients-with-prior-colorectal-cancer-a-population-based-cohort-study
#15
Jiao Yang, Shuting Li, Meng Lv, Yinying Wu, Zheling Chen, Yanwei Shen, Biyuan Wang, Ling Chen, Min Yi, Jin Yang
BACKGROUND: The site-distribution pattern and relative risk of subsequent primary malignancies (SPMs) in colorectal cancer (CRC) patients remains to be determined. MATERIALS AND METHODS: A population-based cohort of 288,390 CRC patients diagnosed between 1973 and 2012 from the Surveillance, Epidemiology, and End Results database was retrospectively reviewed. Standardized incidence ratios were calculated to estimate the relative risk for SPMs. RESULTS: The overall risk of SPMs increased in CRC patients (standardized incidence ratio 1...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28351831/protocol-for-combined-analysis-of-foxfire-sirflox-and-foxfire-global-randomized-phase-iii-trials-of-chemotherapy-selective-internal-radiation-therapy-as-first-line-treatment-for-patients-with-metastatic-colorectal-cancer
#16
Pradeep S Virdee, Joanna Moschandreas, Val Gebski, Sharon B Love, E Anne Francis, Harpreet S Wasan, Guy van Hazel, Peter Gibbs, Ricky A Sharma
BACKGROUND: In colorectal cancer (CRC), unresectable liver metastases are associated with a poor prognosis. The FOXFIRE (an open-label randomized phase III trial of 5-fluorouracil, oxaliplatin, and folinic acid +/- interventional radioembolization as first-line treatment for patients with unresectable liver-only or liver-predominant metastatic colorectal cancer), SIRFLOX (randomized comparative study of FOLFOX6m plus SIR-Spheres microspheres versus FOLFOX6m alone as first-line treatment in patients with nonresectable liver metastases from primary colorectal carcinoma), and FOXFIRE-Global (assessment of overall survival of FOLFOX6m plus SIR-Spheres microspheres versus FOLFOX6m alone as first-line treatment in patients with nonresectable liver metastases from primary colorectal carcinoma in a randomized clinical study) clinical trials were designed to evaluate the efficacy and safety of combining first-line chemotherapy with selective internal radiation therapy (SIRT) using yttrium-90 resin microspheres, also called transarterial radioembolization...
March 28, 2017: JMIR Research Protocols
https://www.readbyqxmd.com/read/28343889/feasibility-safety-and-efficacy-of-two-stage-hepatectomy-for-bilobar-liver-metastases-of-colorectal-cancer-a-livermetsurvey-analysis
#17
Jean Marc Regimbeau, Cyril Cosse, Gernot Kaiser, Catherine Hubert, Christophe Laurent, Real Lapointe, Helen Isoniemi, Rene Adam
BACKGROUND: The combination of liver resection and chemotherapy has become the standard of care for colorectal liver metastases (LM). The objective of the present study was to evaluate the impact of TSH on the long-term survival of patients with bilobar LM. METHODS: We included adult (over-18) patients from the LiverMetSurvey registry with confirmed multiple colorectal LM and having undergone either one-stage hepatectomy or TSH with curative intent. The "TSH (2/2)" group (n = 625) comprised patients having completed both stages of TSH; the "TSH (1/2)" group (n = 244) comprised patients having undergone only the first stage of TSH; the "hepatectomy" group...
March 23, 2017: HPB: the Official Journal of the International Hepato Pancreato Biliary Association
https://www.readbyqxmd.com/read/28288461/clinical-pattern-of-recurrent-disease-during-the-follow-up-of-rectal-carcinoma
#18
Thijs Wieldraaijer, Pascal Bruin, Laura A M Duineveld, Pieter J Tanis, Anke B Smits, Henk C P M van Weert, Jan Wind
BACKGROUND/AIMS: Several initiatives have started to transfer colorectal cancer follow-up (FU) from secondary to primary care. For this purpose, it is important to assess when and how recurrences of rectal carcinoma are detected after treatment with curative intent. METHODS: Retrospective multicentre cohort study. Patients participating in an FU programme after curative intended treatment for rectal cancer stages I-III between 2007 and 2014. RESULTS: Of the 378 patients, 64 (17%) developed recurrent disease (RD)...
March 14, 2017: Digestive Surgery
https://www.readbyqxmd.com/read/28283691/-modulation-of-the-intestinal-microbiota-by-nutritional-interventions
#19
S Derer, H Lehnert, C Sina, A E Wagner
Humans live in symbiosis with billions of commensal bacteria. The so-called microbiota live on different biological interfaces such as the skin, the urogenital tract and the gastrointestinal tract. Commensal bacteria replace potentially pathogenic microbes, synthesize vitamins and ferment dietary fibre. An imbalance in the bacterial composition of the intestinal microbiota has been associated with various diseases including gut-associated disorders such as inflammatory bowel diseases, colorectal cancer and nonalcoholic fatty liver disease...
March 10, 2017: Der Internist
https://www.readbyqxmd.com/read/28237539/rationale-for-and-design-of-the-paradigm-study-randomized-phase-iii-study-of-mfolfox6-plus-bevacizumab-or-panitumumab-in-chemotherapy-na%C3%A3-ve-patients-with-ras-kras-nras-wild-type-metastatic-colorectal%C3%A2-cancer
#20
Takayuki Yoshino, Hiroyuki Uetake, Katsuya Tsuchihara, Kohei Shitara, Kentaro Yamazaki, Eiji Oki, Takeo Sato, Takeshi Naitoh, Yoshito Komatsu, Takeshi Kato, Kazunori Yamanaka, Kouji Iwasaki, Jumpei Soeda, Masamitsu Hihara, Takeharu Yamanaka, Atsushi Ochiai, Kei Muro
BACKGROUND: It remains unclear whether an anti-VEGF or anti-EGFR antibody with standard doublet chemotherapy is the optimal first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer (mCRC). Here we outline the PARADIGM study (NCT02394795), designed to evaluate the superiority of panitumumab over bevacizumab, in combination with oxaliplatin/5-fluorouracil/leucovorin (mFOLFOX6) in patients with RAS wild-type chemotherapy-naïve mCRC. PATIENTS AND METHODS: Eligible patients are aged 20 to 79 years with an ECOG performance status of 0-1 and histologically/cytologically confirmed RAS wild-type mCRC...
January 24, 2017: Clinical Colorectal Cancer
keyword
keyword
61684
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"